Fawcett, Jonathan

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial

Kelley, R. K., Rimassa, L., Cheng, A.-L., Kaseb, A., Qin, S., Zhu, A. X., Chan, S. L., Melkadze, T., Sukeepaisarnjaroen, W., Breder, V., et al. (2022) · The Lancet Oncology

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 535

CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan

Vennin, C., Mélénec, P., Rouet, R., Nobis, M., Cazet, A. S., Murphy, K. J., Herrmann, D., Reed, D. A., Lucas, M. C., Warren, S. C., et al. (2019) · Nature Communications

Pancreatic and Hepatic Oncology ResearchCancer Cells and Metastasis

Cited by 268

Tumor progression in hepatocellular carcinoma: Relationship with tumor stroma and parenchymal disease

LOCKWOOD, D. S., YEADON, T. M., CLOUSTON, A. D., CRAWFORD, D. G., FAWCETT, J., CALLAGHAN, S. A., & GOTLEY, D. C. (2003) · Journal of Gastroenterology and Hepatology

Hepatocellular Carcinoma Treatment and PrognosisLiver physiology and pathology

Cited by 44